NKTX Key Statistics, Chart & Performance
The current stock price of NKTX is 1.83 USD. In the past month the price decreased by -5.64%. In the past year, price decreased by -28.68%.
NKTX Latest News, Press Relases and Analysis
NKTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.98 | 400.53B | ||
| AMGN | AMGEN INC | 15.21 | 179.17B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.2 | 115.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.02 | 75.77B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 901.75 | 60.76B | ||
| INSM | INSMED INC | N/A | 43.74B | ||
| NTRA | NATERA INC | N/A | 33.42B | ||
| BIIB | BIOGEN INC | 10.91 | 26.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.49 | 21.01B | ||
| INCY | INCYTE CORP | 16 | 20.17B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About NKTX
Company Profile
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 110 full-time employees. The company went IPO on 2020-07-10. The firm is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
Company Info
NKARTA INC
1150 Veterans Boulevard
South San Francisco CALIFORNIA 94080 US
CEO: Paul J. Hastings
Employees: 109
Phone: 19254071049
NKARTA INC / NKTX FAQ
What does NKARTA INC do?
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 110 full-time employees. The company went IPO on 2020-07-10. The firm is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
Can you provide the latest stock price for NKARTA INC?
The current stock price of NKTX is 1.83 USD. The price decreased by -0.54% in the last trading session.
Does NKARTA INC pay dividends?
NKTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of NKTX stock?
NKTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of NKARTA INC (NKTX)?
NKARTA INC (NKTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.38).
Is NKARTA INC (NKTX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NKTX.
NKTX Technical Analysis
NKTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NKTX. No worries on liquidiy or solvency for NKTX as it has an excellent financial health rating, but there are worries on the profitability.
NKTX Financial Highlights
Over the last trailing twelve months NKTX reported a non-GAAP Earnings per Share(EPS) of -1.38. The EPS increased by 26.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.02% | ||
| ROE | -30.37% | ||
| Debt/Equity | 0 |
NKTX Forecast & Estimates
13 analysts have analysed NKTX and the average price target is 12.04 USD. This implies a price increase of 557.7% is expected in the next year compared to the current price of 1.83.